← All trials
NCT06723392
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2025
- Primary completion
- Jun 30, 2028
- Completion date
- Aug 31, 2028
- First posted
- Dec 9, 2024
- Last posted
- Dec 9, 2024
- Enrollment
- 1134
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Child Health and Human Development (NICHD)Lead sponsor
- Thomas Jefferson UniversityCollaborator
- University of VirginiaCollaborator
- University Teaching Hospital, Lusaka, ZambiaCollaborator
- University of Colorado, DenverCollaborator
- Aga Khan UniversityCollaborator
- University of North Carolina at Chapel HillCollaborator
- Boston UniversityCollaborator
- International Center for Diarrheal Disease ResearchCollaborator
- Columbia UniversityCollaborator
- Institute of Nutrition of Central America and PanamaCollaborator
- Lata Medical Research Foundation, Nagpur, IndiaCollaborator
- RTI InternationalCollaborator
- University of Alabama, BirminghamCollaborator
- University of KinshasaCollaborator
- Jawaharlal Nehru Medical CollegeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.